| Bioactivity | PIP4K-IN-a131 is PIP4K lipid kinases inhibitor, with IC50s of 1.9 µM and 0.6 µM for purified PIP4K2A and PIP4Ks, respectively. PIP4K-IN-a131 exhibits cancer-selective lethality via dual blockade of the lipid kinase PIP4Ks and mitotic pathways[1]. | ||||||
| Target | IC50: 1.9 µM (PIP4K2A), 0.6 µM (PIP4Ks) | ||||||
| Invitro | PIP4K-IN-a131 (0-100 μM; 72 hours) is a potent antiproliferative agent with a clear selectivity toward cancer cells killing[1].PIP4K-IN-a131 eliminates cancer cells via a dual-inhibitory mechanism[1].PIP4K-IN-a131 causes inhibition of the PI3K/Akt/mTOR pathway only in normal BJ cells, but not in transformed counterparts[1].Inhibition of PIP4Ks by PIP4K-IN-a131 arrests normal cells at the G1/S phase of the cell cycle by suppressing the PI3K/Akt/mTOR signaling pathway via transcriptional upregulation of PIK3IP1[1]. Cell Proliferation Assay[1] Cell Line: | ||||||
| Name | PIP4K-IN-a131 | ||||||
| CAS | 2055405-95-1 | ||||||
| Formula | C20H13N3 | ||||||
| Molar Mass | 295.34 | ||||||
| Appearance | Solid | ||||||
| Transport | Room temperature in continental US; may vary elsewhere. | ||||||
| Storage |
*该产品在溶液状态不稳定，建议您现用现配，即刻使用。 |
||||||
| Reference | [1]. Mayumi Kitagawa, et al. Dual Blockade of the Lipid Kinase PIP4Ks and Mitotic Pathways Leads to Cancer-Selective Lethality. Nat Commun. 2017 Dec 19;8(1):2200. |